Spur Therapeutics Limited

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

After a recent series B round, Beacon Therapeutics has boosted its finances by $170m, bringing its total funding to date to $290m, as it looks to advance in the crowded field of gene therapies for t

Decent-sized fundraisings have been few and far between in Europe of late but the Swiss/Dutch cancer specialist iOnctura SA has bucked the trend with a €80m series B financing. The round was led by

Keeping with the trend of combining companies to help financially constrained biotechs stay afloat, investment major Syncona has again come to the rescue of Freeline Therapeutics Holdings PLC and me